UTHR insider exercises 8,000 options and sells 8,000 shares
Rhea-AI Filing Summary
United Therapeutics (UTHR) reported insider transactions by its Chairperson & CEO (also a Director). On 10/13/2025 and 10/14/2025, the executive exercised 4,000 stock options each day at an exercise price of $120.26 per share (total 8,000 shares), and sold a total of 8,000 shares in multiple trades. Reported sale prices included $437.53, $441.26, $432.74, and weighted averages of $441.4 (range $441.085–$442.07) and $434.0077 (range $434.00–$434.145).
Following these transactions, direct holdings were 130 shares. Indirect holdings were reported as 166 shares by spouse and trusts holding 324,518, 258,117, 45,596, and 15,962 shares. Derivative securities beneficially owned following the reported transactions totaled 186,000 stock options.
The activity was conducted under a pre-arranged Rule 10b5-1 trading plan entered on May 2, 2025, which continues until the earlier of exhausting a 294,000-option tranche expiring March 15, 2026, or December 31, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 4,000 | $0.00 | -- |
| Exercise | Common Stock | 4,000 | $120.26 | $481K |
| Sale | Common Stock | 522 | $432.74 | $226K |
| Sale | Common Stock | 1,478 | $434.0077 | $641K |
| Sale | Common Stock | 2,000 | $441.26 | $883K |
| Exercise | Stock Option | 4,000 | $0.00 | -- |
| Exercise | Common Stock | 4,000 | $120.26 | $481K |
| Sale | Common Stock | 1,000 | $437.53 | $438K |
| Sale | Common Stock | 3,000 | $441.40 | $1.32M |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025. This plan will continue until the earlier of: (a) exhaustion of a tranche of 294,000 stock options that expire March 15, 2026; or (b) December 31, 2025. This transaction was executed in multiple trades at prices ranging from $441.085 to $442.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $434.00 to $434.145. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
